What is claimed is:

1. A compound of structural Formula I:



I

or pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of

1) $-C(O)OCH_2OC(O)R^2$;
2) $-C(O)OC_{1-6}$ alkyl, said alkyl optionally substituted with 1 to 3 groups of R^a, wherein the C_{1-6} alkyl of $-C(O)OC_{1-6}$ alkyl is not t-butyl~~.~~,
3) $-C(O)-C_{6-10}$ aryl, $C(O)-$~~C_6~~C_{4-10}heteroaryl, $-C(O)-C_{1-6}$ alkyl, $-C(O)-C_{3-6}$ cycloalkyl said aryl, heteroaryl, alkyl and cycloalkyl optionally substituted with 1 to 3 groups of R^a;
4) $-S-C_{6-10}$ aryl, $-S-C_{4-10}$heteroaryl, $-S-C_{1-6}$ alkyl, $-S-C_{3-6}$ cycloalkyl said aryl, heteroaryl, alkyl and cycloalkyl optionally substituted with 1 to 3 groups of R^a; and
5) $-C(O)OCH_2$dioxolyl, optionally substituted with 1 to 2 groups of R^a;

R^2 is selected from the group consisting of C_{1-6} alkyl, C_{6-10} aryl, ~~C_6~~C_{4-10} heteroaryl, and C_{3-6} cycloalkyl; said alkyl, aryl heteroaryl, and cycloalkyl optionally substituted with 1 to 3 groups of R^a;

R^a is independently selected from the group consisting of C_{1-6} alkyl, OC_{1-6} alkyl, oxo, and halogen. ~~;~~

~~n is 1, 2, 3, or 4.~~

2. The compound according to claim 1 wherein R^1 is $-C(O)OCH_2OC(O)R^2$~~.~~, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 and 2 wherein R^2 is C_{6-10} aryl, said aryl unsubstituted or substituted with 1 to 3 groups of R^a~~.~~,
or a pharmaceutically acceptable salt thereof.

4. The compound according to any one of claims 1 through 3 wherein R^2 is ~~the aryl is~~ phenyl or naphthyl, said phenyl and naphthyl unsubstituted or substituted with 1 to 3 groups of R^a~~.~~
or a pharmaceutically acceptable salt thereof.

5. The compound according to any one of claims 1 through 4 wherein the R^2 is~~aryl is phenyl said~~ phenyl, unsubstituted or substituted with 1 to 3 groups of R^a~~.~~ ,
or a pharmaceutically acceptable salt thereof.

6. The compound according to any one of claims 1 ~~and~~ or 2 wherein R^2 is $C_{1\text{-}6}$ alkyl, ~~said alkyl~~ unsubstituted or substituted with 1 to 3 groups of R^a~~.~~,
or a pharmaceutically acceptable salt thereof.

7. The compound according to any one of claims 1 ~~and~~ or 2, wherein R^2 is $C_{4\text{-}10}$ heteroaryl, ~~said heteroaryl~~ unsubstituted or substituted with 1 to 3 groups of R^a~~.~~,
or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 7 wherein the R^2 is~~heteroaryl is~~ pyridyl ~~and~~ or pyrimidinyl wherein pyridyl and pyrimidinyl are unsubstituted or substituted with 1 to 3 groups of R^a~~.~~,
or a pharmaceutically acceptable salt thereof.

9. The compound according to claim~~s~~ 1 and 2 wherein R^2 is $C_{3\text{-}6}$ cycloalkyl; said cycloalkyl unsubstituted or substituted with 1 to 3 groups of R^a~~.~~ ,
or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 9 wherein the R^2 is ~~cycloalkyl is selected from the group consisting of unsubstituted or substituted~~ cyclobutyl, cyclopentyl or cyclohexyl, wherein cyclobutyl, cyclopentyl and cyclohexyl are unsubstituted or substituted with 1 to 3 groups of R^a,

or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 wherein R^1 is -$C(O)OC_{1-6}$ alkyl, said alkyl optionally substituted with 1 to 3 groups of R^a, wherein the C_{1-6} alkyl of -$C(O)OC_{1-6}$ alkyl is not t-butyl.,
or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1 when R^1 is -S-C_{6-10} aryl or -C(O)-C_{6-10} aryl ~~said~~ wherein said aryl is optionally substituted with 1 to 3 groups of R^a.~~—~~,
or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 12 wherein ~~the~~ aryl is phenyl or naphthyl, said phenyl ~~and~~ or naphthyl unsubstituted or substituted with 1 to 3 groups of R^a.~~—~~,
or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 wherein R^1 is -$C(O)OCH_2$dioxolyl, said dioxolyl unsubstituted or substituted with 1 to 3 groups of R^a.~~—~~,
or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 that is:
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl ((5-methyl-1,3,4-thiadiazol-2-yl)methyl)(2-methyl-6-(((1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-yl)carbamate;
N-((5-Methyl-1,3,4-thiadiazol-2-yl)methyl)-*N*-(2-methyl-6-(((1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-yl)-*S*-phenylthiohydroxylamine;
N-((5-Methyl-1,3,4-thiadiazol-2-yl)methyl)-*N*-(2-methyl-6-(((1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-yl)benzamide;
Pentyl ((5-methyl-1,3,4-thiadiazol-2-yl)methyl)(2-methyl-6-(((1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-yl)carbamate;
((((5-Methyl-1,3,4-thiadiazol-2-yl)methyl)(2-methyl-6-(((1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-yl)carbamoyl)oxy)methyl benzoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl hexanoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl propanoate;

({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl pyridine-4-carboxylate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl pyridine-2-carboxylate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl pyridine-3-carboxylate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 4-fluorobenzoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 3-fluorobenzoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 2-fluorobenzoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 2-methoxybenzoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 3-methoxybenzoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 4-methoxybenzoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 2-methylpropanoate;
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl cyclohexanecarboxylate; or
({(2-Methyl-6-{[(1*S*,2*S*)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-yl)[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}oxy)methyl 2-ethylbutanoate;
or a pharmaceutically acceptable salt thereof.

16. A compound, selected from



,



,



,



,



,



,



, and



,

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.

18. The pharmaceutical composition according to claim 17, wherein the compound is:



,



,



,



,



,



,



, or



,

or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 16 which is:



,



,



,



,



,



,



, or



.

.

20. Use of a compound of any one of claims 1 to 16 or 19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder selected from psychotic disorders, delusional disorders, drug induced psychosis, anxiety disorders, movement disorders and neurodegenerative disorders.

21. Use of a compound of any one of claims 1 to 16 or 19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of schizophrenia.

22. A compound of any one of claims 1-16 or 19, or a pharmaceutically acceptable salt thereof, for use in therapy.